Sun Pharmaceutical Industries Limited has informed the Exchange about Updates on Fibromun and Nidlegy

Sun Pharma shared clinical updates from its partner Philogen on two drugs. For Fibromun, two Phase II studies failed to meet their primary goals: the FLASH study in last-line soft tissue sarcoma (94 patients) and the GLIOSTAR study in second-line glioblastoma (163 patients). However, the GLIOSUN trial in first-line glioblastoma is progressing into dose expansion, and a new Phase III study (FIBROSARC-2) is being planned after encouraging survival signals in liposarcoma patients. For Nidlegy (a skin cancer treatment), the company is preparing a fresh European submission after a 2025 withdrawal, and the Phase III melanoma trial in the US, Spain, and Switzerland is ongoing after a constructive FDA meeting in March 2026. In non-melanoma skin cancer, the 'Duncan' study in basal cell carcinoma showed complete pathological responses in 52.6% of patients, and three new registrational studies are expected to start in Q2 2026, with a fourth expected mid-2026.